Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Research indicates that GLP-1 diabetes drugs such as tirzepatide and semaglutide may reduce surgical complications in diabetic patients. Insulin proves superior to oral medication for managing ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive data from a 12-week Phase 2a ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...